Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 4Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Thoracic 3Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cytarabine 465Cyclophosphamide 459fludarabine phosphate 277Rituximab 249Methotrexate 245Etoposide 203fludarabine 200Filgrastim 199Peripheral Blood Stem Cell Transplantation 180Busulfan 169Vincristine 163Dexamethasone 153Daunorubicin 151Azacitidine 145Mycophenolic Acid 142Whole-Body Irradiation 133Tacrolimus 127Imatinib Mesylate 127Cyclosporine 123Granulocyte Colony-Stimulating Factor 118Radiotherapy 113Melphalan 110Idarubicin 103Doxorubicin 101Mitoxantrone 97Antilymphocyte Serum 97Lenalidomide 96Decitabine 96Mercaptopurine 93Prednisone 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × obatoclax × Other hematologic neoplasm × Clear all
NCT00438178 2014-05-12

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
44 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00600964 2014-05-12

A Phase I/II Study of GX15-070MS in Untreated CLL

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00684918 2013-08-26

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡